Results 91 to 100 of about 769,860 (308)

Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein [PDF]

Clinical Chemistry, 1998
Abstract Cardiovascular disease is the leading cause of morbidity and mortality in Westernized populations. Evolving lipoprotein risk factors include LDL oxidation and lipoprotein(a) [lp(a)]. Several lines of evidence support a role for oxidatively modified LDL in atherogenesis and its in vivo existence.
openaire   +2 more sources

Acute lower limb ischemia due to thrombo-embolic arterial occlusions in two previously healthy men with markedly elevated Lp(a) [PDF]

, 2006
Lipoprotein (a) (Lp(a)) is a well-documented risk factor for atherosclerotic cardiovascular disease. Its role in acute thrombo-embolic occlusions of peripheral arteries is not known.
Federico Tatò, Gabriella V Bedarida, Igarashi Y, Koschinsky ML, Krause M, Novak-Gottl U, Ulrich Hoffmann   +6 more
core   +4 more sources

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Moderate exercise increases affinity of large very low density lipoproteins for hydrolysis by lipoprotein lipase [PDF]

, 2015
Context: Postprandial triglyceride (TG) concentration is independently associated with cardiovascular disease risk. Exercise reduces postprandial TG concentrations but the mechanisms responsible are unclear.
Bedford, Dorothy K., Caslake, Muriel J., Cooney, Josephine, GHAFOURI, Khloud, Gill, Jason M.R., Wilson, John   +5 more
core   +1 more source

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

Advanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang, Wing Yan Chung, Serena M. Pulente, Yubin Lei, Khang Nguyen, Eddie Tam, Nadya M. Morrow, Ilka Lorenzen‐Schmidt, Fengxia Xiao, Augusto Zani, Dylan Burger, Hye Kyoung Sung, Erin E. Mulvihill, Gary Sweeney   +13 more
wiley   +1 more source

Analysis of α-lipoprotein cholesterol in 50 μl of plasma

Journal of Lipid Research, 1974
A micromethod for quantitation of α-lipoprotein cholesterol was devised for gas–liquid chromatography to minimize plasma sample size and facilitate lipid studies using capillary blood from children or small animals. α-Lipoprotein cholesterol was measured
R.F. Lutmer, D. Parsons, C.J. Glueck, J.A. Morrison, L. Stewart, J.B. Brazier, C.R. Buncher, T.T. Ishikawa   +7 more
doaj   +1 more source

Measurement of low‐density lipoprotein cholesterol levels in primary and secondary prevention patients: Insights from the PALM registry [PDF]

, 2018
Background The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommended testing low-density lipoprotein cholesterol ( LDL -C) to ...
Goldberg, Anne C, Lee, L. Veronica, Li, Shuang, Louie, Michael J, Lowenstern, Angela M, Navar, Ann Marie, Peterson, Eric D, Robinson, Jennifer G, Roger, Veronique L, Virani, Salim S, Wang, Tracy Y, Wilson, Peter W.F.   +11 more
core   +2 more sources

CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads

Advanced Healthcare Materials, EarlyView.
In this paper researchers introduce CORE LNPs, a new class of lipid nanoparticles engineered to redirect mRNA expression away from the liver and into the spleen, a key immune organ. By combining chemical design with computational tools, they created cholesterol analogs that enable precise spleen‐targeted expression, providing greater applications for ...
Eshan A. Narasipura, Vincent Fung, Rachel VanKeulen‐Miller, Palas B. Tiwade, Owen S. Fenton   +4 more
wiley   +1 more source

Phosphatidylinositol promotes cholesterol transport in vivo

Journal of Lipid Research, 2000
To examine the role that lipoprotein charge plays in cholesterol metabolism in vivo, we characterized the effects of an intravenous injection of 40 μmol of an uncharged phospholipid (phosphatidylcholine, PC) or an anionic phospholipid ...
Christopher J. Stamler, Dalibor Breznan, Tracey A-M. Neville, France J. Viau, Errol Camlioglu, Daniel L. Sparks   +5 more
doaj   +1 more source

HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". [PDF]

, 2016
BackgroundProprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population.
Deeks, Steven, Ganz, Peter, Grunfeld, Carl, Hsue, Priscilla Y, Hur, Sophia, Kohli, Payal, Ma, Yifei, Scherzer, Rebecca, Scott, Rob, Wasserman, Scott, Weigel, Bernard   +10 more
core   +1 more source